• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉内和肺内注射重组组织型纤溶酶原激活剂治疗急性大面积肺栓塞。

Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.

作者信息

Verstraete M, Miller G A, Bounameaux H, Charbonnier B, Colle J P, Lecorf G, Marbet G A, Mombaerts P, Olsson C G

机构信息

Center for Thrombosis and Vascular Research, Campus Gasthuisberg, Leuven, Belgium.

出版信息

Circulation. 1988 Feb;77(2):353-60. doi: 10.1161/01.cir.77.2.353.

DOI:10.1161/01.cir.77.2.353
PMID:3123091
Abstract

Eight centers participated in a study in which intrapulmonary and intravenous administration of recombinant tissue-type plasminogen activator (rt-PA) were compared in 34 patients with acute massive pulmonary embolism. All patients received intravenous heparin in a bolus of 5,000 IU followed by 1,000 IU/hr. After 50 mg rt-PA given over 2 hr the severity of embolism, determined from pulmonary angiograms, declined by 12% in the intrapulmonary drug group (p less than .005) and 15% in the intravenous drug group (p less than .005); mean pulmonary arterial pressure fell from 31 +/- 7 to 22 +/- 6 mm Hg (p less than .005) and from 31 +/- 12 to 21 +/- 9 mm Hg (p less than .005) in the respective groups. After a further 50 mg given over 5 hr (22 patients), the angiographically determined severity of embolism had decreased by 38% from baseline in the intrapulmonary drug group and by 38% in the intravenous drug group. The mean pulmonary arterial pressure further declined to 18 +/- 7 and 12 +/- 5 mm Hg in the respective groups. Fibrinogen levels dropped to 48% of baseline after 50 mg and to 36% of baseline after 100 mg rt-PA. Some degree of bleeding at puncture and/or operation sites was noted in 16 patients, including four who required a transfusion of two or more units of blood and had been operated on an average of 7.5 days (range 2 to 13) before thrombolytic treatment was started.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

八个中心参与了一项研究,该研究对34例急性大面积肺栓塞患者进行了肺内和静脉注射重组组织型纤溶酶原激活剂(rt-PA)的比较。所有患者均静脉推注5000 IU肝素,随后以1000 IU/小时的速度持续静脉滴注。在2小时内给予50 mg rt-PA后,根据肺血管造影确定,肺内给药组的栓塞严重程度下降了12%(p<0.005),静脉给药组下降了15%(p<0.005);相应组的平均肺动脉压分别从31±7降至22±6 mmHg(p<0.005)和从31±12降至21±9 mmHg(p<0.005)。在另外5小时内给予50 mg(22例患者)后,肺内给药组经血管造影确定的栓塞严重程度较基线下降了38%,静脉给药组也下降了38%。相应组的平均肺动脉压进一步降至18±7和12±5 mmHg。给予50 mg rt-PA后纤维蛋白原水平降至基线的48%,给予100 mg后降至基线的36%。16例患者在穿刺和/或手术部位出现了一定程度的出血,其中4例需要输注两单位或更多单位的血液,并且在开始溶栓治疗前平均7.5天(范围2至13天)接受了手术。(摘要截短于250字)

相似文献

1
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.静脉内和肺内注射重组组织型纤溶酶原激活剂治疗急性大面积肺栓塞。
Circulation. 1988 Feb;77(2):353-60. doi: 10.1161/01.cir.77.2.353.
2
Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism.大面积肺栓塞溶栓治疗后患者静息及运动时肺血流动力学的持续改善
Circulation. 1985 Jan;71(1):117-23. doi: 10.1161/01.cir.71.1.117.
3
Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.低剂量推注阿替普酶与传统阿替普酶静脉输注用于肺栓塞溶栓治疗的比较:一项国际多中心随机试验。推注阿替普酶治疗肺栓塞研究组
Chest. 1994 Sep;106(3):718-24. doi: 10.1378/chest.106.3.718.
4
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
J Am Coll Cardiol. 1992 Sep;20(3):520-6. doi: 10.1016/0735-1097(92)90002-5.
5
Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators.组织型纤溶酶原激活剂治疗急性肺栓塞。PIOPED研究人员的一项合作研究。
Chest. 1990 Mar;97(3):528-33. doi: 10.1378/chest.97.3.528.
6
Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator.
J Am Coll Cardiol. 1987 Nov;10(5):971-8. doi: 10.1016/s0735-1097(87)80333-9.
7
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
Chest. 1990 Dec;98(6):1473-9. doi: 10.1378/chest.98.6.1473.
8
Thrombolytic therapy of acute pulmonary embolism: current status and future potential.急性肺栓塞的溶栓治疗:现状与未来潜力
J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):96B-104B. doi: 10.1016/s0735-1097(87)80434-5.
9
Acute pulmonary embolism treated with tissue plasminogen activator.用组织型纤溶酶原激活剂治疗急性肺栓塞。
Lancet. 1986 Oct 18;2(8512):886-9. doi: 10.1016/s0140-6736(86)90411-3.
10
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial.
Chest. 1994 Sep;106(3):712-7. doi: 10.1378/chest.106.3.712.

引用本文的文献

1
Acute pulmonary embolism: a paradigm shift in interventional treatment and interdisciplinary care?急性肺栓塞:介入治疗与多学科护理的范式转变?
Eur Radiol. 2025 May 9. doi: 10.1007/s00330-025-11548-7.
2
Management of high-risk pulmonary embolism in the emergency department: A narrative review.急诊科高危肺栓塞的管理:一项叙述性综述。
Am J Emerg Med. 2024 May;79:1-11. doi: 10.1016/j.ajem.2024.01.039. Epub 2024 Feb 3.
3
Interventional therapies in acute pulmonary embolus-current trends and future directions.急性肺栓塞的介入治疗——当前趋势和未来方向。
Br J Radiol. 2023 Sep;96(1149):20221151. doi: 10.1259/bjr.20221151. Epub 2023 Jul 14.
4
A retrospective analysis of fibrinolytic and adjunctive antithrombotic treatment during cardiopulmonary resuscitation.心肺复苏期间溶栓和辅助抗血栓治疗的回顾性分析。
Sci Rep. 2021 Dec 16;11(1):24095. doi: 10.1038/s41598-021-03580-6.
5
Thrombolytic therapy for pulmonary embolism.肺栓塞的溶栓治疗。
Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD004437. doi: 10.1002/14651858.CD004437.pub6.
6
Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital.极大出血风险患者中的大面积肺栓塞:在一家地区综合医院中,成功使用超声辅助、导管定向溶栓治疗的病例系列。
J Thromb Thrombolysis. 2021 May;51(4):1120-1126. doi: 10.1007/s11239-020-02258-6.
7
Thrombolytic therapy for pulmonary embolism.肺栓塞的溶栓治疗
Cochrane Database Syst Rev. 2018 Dec 18;12(12):CD004437. doi: 10.1002/14651858.CD004437.pub5.
8
Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper.了解中高危肺栓塞患者溶栓治疗后的出血风险:一篇假说论文。
Open Heart. 2018 Feb 26;5(1):e000735. doi: 10.1136/openhrt-2017-000735. eCollection 2018.
9
Endovenous Treatment for Acute Massive Pulmonary Thromboembolism.急性大面积肺血栓栓塞症的静脉内治疗
Ann Vasc Dis. 2017 Dec 25;10(4):338-344. doi: 10.3400/avd.ra.17-00082.
10
How I use catheter-directed interventional therapy to treat patients with venous thromboembolism.我如何使用导管定向介入治疗来治疗静脉血栓栓塞症患者。
Blood. 2018 Feb 15;131(7):733-740. doi: 10.1182/blood-2016-11-693663. Epub 2018 Jan 2.